| Year |
Citation |
Score |
| 2022 |
Kirpotin DB, Hayes ME, Noble CO, Huang ZR, Wani K, Moore D, Kesper K, Brien DO, Drummond DC. Drug Stability and Minimized Acid-/Drug-Catalyzed Phospholipid Degradation in Liposomal Irinotecan. Journal of Pharmaceutical Sciences. PMID 36462709 DOI: 10.1016/j.xphs.2022.11.025 |
0.702 |
|
| 2019 |
Camblin AJ, Tan G, Curley MD, Yannatos I, Iadevaia S, Rimkunas V, Mino-Kenudson M, Bloom T, Schoeberl B, Drummond DC, Lugovskoy AA, Louis CU, Askoxylakis V. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Scientific Reports. 9: 16832. PMID 31728045 DOI: 10.1038/S41598-019-53322-Y |
0.329 |
|
| 2019 |
Kamoun WS, Dugast AS, Suchy JJ, Grabow S, Fulton RB, Sampson JF, Luus L, Santiago M, Koshkaryev A, Sun G, Askoxylakis V, Tam E, Huang ZR, Drummond DC, Sawyer AJ. Synergy between EphA2-ILs-DTXp, a novel EphA2 targeted nanoliposomal taxane, and PD-1 inhibitors in preclinical tumor models. Molecular Cancer Therapeutics. PMID 31597714 DOI: 10.1158/1535-7163.Mct-19-0414 |
0.37 |
|
| 2019 |
Tam EM, Fulton RB, Sampson JF, Muda M, Camblin A, Richards J, Koshkaryev A, Tang J, Kurella V, Jiao Y, Xu L, Zhang K, Kohli N, Luus L, Hutto E, ... ... Drummond DC, et al. Antibody-mediated targeting of TNFR2 activates CD8 T cells in mice and promotes antitumor immunity. Science Translational Medicine. 11. PMID 31578241 DOI: 10.1126/Scitranslmed.Aax0720 |
0.335 |
|
| 2019 |
Huang ZR, Tipparaju SK, Kirpotin DB, Pien C, Kornaga T, Noble CO, Koshkaryev A, Tran J, Kamoun WS, Drummond DC. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 31400383 DOI: 10.1016/J.Jconrel.2019.08.006 |
0.726 |
|
| 2019 |
Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, ... ... Drummond DC, et al. Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Nature Biomedical Engineering. 3: 264-280. PMID 30952988 DOI: 10.1038/S41551-019-0385-4 |
0.734 |
|
| 2019 |
Dumont N, Merrigan S, Turpin J, Lavoie C, Papavasiliou V, Geretti E, Espelin C, Luus L, Kamoun W, Ghasemi O, Sahagian GG, Muller W, Hendriks B, Wickham TJ, Drummond DC. Nanoliposome targeting in breast Cancer is influenced by the tumor microenvironment. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 30654182 DOI: 10.1016/J.Nano.2018.12.010 |
0.47 |
|
| 2019 |
Koshkaryev A, Alkan O, Geng B, Luus L, Raue A, Kamoun W, Tipparaju S, Kirpotin D, Drummond D. Abstract 8: Targeting DNA-damage response pathway with a novel nano-liposomal ATR inhibitor in solid tumors Cancer Research. 79: 8-8. DOI: 10.1158/1538-7445.Sabcs18-8 |
0.444 |
|
| 2019 |
Sampson JF, Kurella VB, Paragas V, Kumar S, Lulo JE, Qiu JA, Razlog M, Fulton RB, Camblin AJ, Richards JM, Wong CS, Koshkaryev A, Suchy JJ, Grabow S, Muda M, ... ... Drummond DC, et al. Abstract 555: A novel human TNFR2 antibody (MM-401) modulates T cell responses in anti-cancer immunity Cancer Research. 79: 555-555. DOI: 10.1158/1538-7445.Sabcs18-555 |
0.358 |
|
| 2019 |
Richards J, Wong C, Koshkaryev A, Fulton R, Camblin A, Sampson J, Luus L, Suchy J, Grabow S, Kurella V, Kumar S, Lulo J, Qiu J, Jiao Y, Xu L, ... ... Drummond D, et al. Abstract 4846: MM-401, a novel anti-TNFR2 antibody that induces T cell co-stimulation, robust anti-tumor activity and immune memory Cancer Research. 79: 4846-4846. DOI: 10.1158/1538-7445.Sabcs18-4846 |
0.389 |
|
| 2019 |
Fulton RB, Camblin A, Sampson JF, Richards J, Wong C, Koshkaryev A, Luus L, Jiao Y, Xu L, Paragas V, Razlog M, Muda M, Tam EM, Drummond DC, Raue A. Abstract 3270: Mechanism of action of a novel agonist TNFR2 antibody that induces co-stimulation of T cells and promotes robust anti-tumor immunity Cancer Research. 79: 3270-3270. DOI: 10.1158/1538-7445.Am2019-3270 |
0.391 |
|
| 2019 |
Sawyer AJ, Ghassemifar S, Wong C, Richards J, Grabow S, Suchy J, Koshkaryev A, Razlog M, Tam E, Drummond DC. Abstract 2491: Engineering and preclinical activity of MM-201, a best-in-class TRAIL receptor agonist Cancer Research. 79: 2491-2491. DOI: 10.1158/1538-7445.Am2019-2491 |
0.37 |
|
| 2018 |
Kumar MP, Du J, Lagoudas G, Jiao Y, Sawyer A, Drummond DC, Lauffenburger DA, Raue A. Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics. Cell Reports. 25: 1458-1468.e4. PMID 30404002 DOI: 10.1016/J.Celrep.2018.10.047 |
0.339 |
|
| 2018 |
Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, et al. Dual inhibition of IGF-1R and ErbB3 enhances the activity of gemcitabine and nab-paclitaxel in preclinical models of pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29549161 DOI: 10.1158/1078-0432.Ccr-17-2262 |
0.58 |
|
| 2018 |
Kamoun W, Swindell E, Pien C, Luus L, Cain J, Kandela I, Huang R, Tipparaju S, Kirpotin D, Bshara W, Askoxylakis V, Morrison C, Drummond D. Abstract 5771: Targeting EphA2 in bladder cancer using a novel antibody-directed nanotherapeutic Cancer Research. 78: 5771-5771. DOI: 10.1158/1538-7445.Am2018-5771 |
0.481 |
|
| 2018 |
Tam E, Craig G, Ghassemifar S, Koshkaryev A, Movassaghian S, Cosgrove C, Sampson J, Drummond D, Raue A. Abstract 2716: Development of 4-1BB agonists: Ligand fusion shows greater anti-tumor activity than antibodies in vivo Cancer Research. 78: 2716-2716. DOI: 10.1158/1538-7445.Am2018-2716 |
0.375 |
|
| 2017 |
Louis N, Liu S, He X, Drummond DC, Noble CO, Goldman S, Mueller S, Bankiewicz K, Gupta N, Hashizume R. New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model. Journal of Neuro-Oncology. PMID 29170909 DOI: 10.1007/S11060-017-2681-8 |
0.745 |
|
| 2017 |
Leonard SC, Lee H, Gaddy DF, Klinz SG, Paz N, Kalra AV, Drummond DC, Chan DC, Bunn PA, Fitzgerald JB, Hendriks BS. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Anti-Cancer Drugs. PMID 28857767 DOI: 10.1097/Cad.0000000000000545 |
0.495 |
|
| 2017 |
Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemotherapy and Pharmacology. PMID 28233053 DOI: 10.1200/Jco.2015.33.15_Suppl.2029 |
0.717 |
|
| 2017 |
Ramanathan RK, Korn R, Raghunand N, Sachdev JC, Newbold RG, Jameson G, Fetterly GJ, Prey J, Klinz SG, Kim J, Cain J, Hendriks BS, Drummond DC, Bayever E, Fitzgerald JB. Correlation Between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients With Advanced Solid Tumors: A Pilot Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28159813 DOI: 10.1158/1078-0432.Ccr-16-1990 |
0.375 |
|
| 2017 |
Gaddy DF, Lee H, Paz N, Leonard SC, Kalra A, Straubinger NL, Straubinger RM, Gillard BM, Moser MT, Foster BA, Drummond DC, Klinz SG, Hendriks B, Fitzgerald JB. Preclinical antitumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) and utilization as a foundation of front-line pancreatic cancer regimens. Journal of Clinical Oncology. 35: 336-336. DOI: 10.1200/Jco.2017.35.4_Suppl.336 |
0.667 |
|
| 2017 |
Harker-Murray PD, Meyer WH, Leavey P, Kang MH, Cho H, Adiwijaya BS, Fitzgerald JB, Pipas JM, Drummond DC, Reynolds CP. Abstract CT146: Plasma pharmacokinetics of liposomal irinotecan (nal-IRI) in pediatric oncology patients with recurrent or refractory solid tumors: South Plains Oncology Consortium Study 2012-001 Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct146 |
0.373 |
|
| 2017 |
Sawyer AJ, Dugast A, Luus L, Huang ZR, Tipparaju SK, Kirpotin DB, Drummond DC, Kamoun WS. Abstract 4711: Immunomodulatory effects of an EphA2-targeted docetaxel antibody-directed nanotherapeutic and synergistic combination with PD-1 inhibitor Cancer Research. 77: 4711-4711. DOI: 10.1158/1538-7445.Am2017-4711 |
0.343 |
|
| 2017 |
Kamoun WS, Sawyer AJ, Pien C, Koshkaryev A, Luus L, Merrigan S, Sun G, Kozin S, Huang ZR, Tipparaju SK, Kirpotin DB, Xu H, Askoxylakis V, Reynolds PC, Drummond DC. Abstract 3096: Mechanisms of synergy of carboplatin and an EphA2-targeted docetaxel antibody-directed nanotherapeutic Cancer Research. 77: 3096-3096. DOI: 10.1158/1538-7445.Am2017-3096 |
0.514 |
|
| 2016 |
Geddie ML, Kohli N, Kirpotin DB, Razlog M, Jiao Y, Kornaga T, Rennard R, Xu L, Schoerberl B, Marks JD, Drummond DC, Lugovskoy AA. Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. Mabs. 0. PMID 27854147 DOI: 10.1080/19420862.2016.1259047 |
0.389 |
|
| 2016 |
Kamoun WS, Luus L, Pien C, Kornaga T, Oyama S, Huang ZR, Tipparaju S, Kirpotin DB, Marks JD, Koshkaryev A, Geddie M, Xu L, Lugovosky A, Drummond DC. Abstract 871: Nanoliposomal targeting of ephrin receptor A2 (EphA2): Preclinical in vitro and in vivo rationale Cancer Research. 76: 871-871. DOI: 10.1158/1538-7445.Am2016-871 |
0.469 |
|
| 2016 |
Kamoun WS, Oyama S, Kornaga T, Feng T, Luus L, Pham MT, Kirpotin DB, Marks JD, Geddie M, Xu L, Lugovskoy AA, Murphy M, Morrisson C, Drummond DC. Abstract 750: Nanoliposomal targeting of Ephrin receptor A2 (EphA2): Clinical translation: Cancer Research. 76: 750-750. DOI: 10.1158/1538-7445.Am2016-750 |
0.425 |
|
| 2016 |
Gaddy DF, Lee H, Paz N, Leonard SC, Kalra A, Straubinger NL, Straubinger RM, Gillard BM, Moser MT, Drummond DC, Klinz SG, Hendriks BS, Fitzgerald JB. Abstract 4830: Preclinical anti-tumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) + 5-FU + oxaliplatin in pancreatic cancer Cancer Research. 76: 4830-4830. DOI: 10.1158/1538-7445.Am2016-4830 |
0.659 |
|
| 2016 |
Kirpotin DB, Tipparaju S, Huang ZR, Kamoun WS, Pien C, Kornaga T, Oyama S, Olivier K, Marks JD, Koshkaryev A, Schihl SS, Fetterly G, Schoeberl B, Noble C, Hayes M, ... Drummond DC, et al. Abstract 3912: MM-310, a novel EphA2-targeted docetaxel nanoliposome Cancer Research. 76: 3912-3912. DOI: 10.1158/1538-7445.Am2016-3912 |
0.743 |
|
| 2016 |
Koshkaryev A, Fitzgerald J, Kim J, Kalra A, Kamoun W, Blanchette S, Luus L, Klinz S, Alkan O, Kornaga T, Bates S, Pommier Y, Drummond DC. Abstract 2075: Differential tissue clearance results in improved therapeutic index for irinotecan liposome injection (ONIVYDE) when combined with the PARP inhibitor veliparib in preclinical cervical tumors Cancer Research. 76: 2075-2075. DOI: 10.1158/1538-7445.Am2016-2075 |
0.466 |
|
| 2016 |
Drummond DC, Straubinger NL, Chaudhuri TR, Moser M, Kamoun WS, Luus L, Huang ZR, Tipparaju S, Gillard B, Morrison C, Repasky E, Kirpotin DB, Straubinger RM. Abstract 2069: Activity of an EphA2-targeted docetaxel nanoliposome in pancreatic patient-derived models as monotherapy and in combination with gemcitabine Cancer Research. 76: 2069-2069. DOI: 10.1158/1538-7445.Am2016-2069 |
0.666 |
|
| 2016 |
Han S, Taylor J, Aghi M, Chang S, Clarke J, Bankiewicz K, Martin A, Drummond D, Fitzgerald J, Butowski N. ACTR-33. A PHASE I STUDY OF CONVECTION-ENHANCED DELIVERY OF LIPOSOMAL-IRINOTECAN USING REAL-TIME IMAGING WITH GADOLINIUM IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 18: vi9-vi9. DOI: 10.1093/Neuonc/Now212.031 |
0.323 |
|
| 2015 |
Kang MH, Wang J, Makena MR, Lee JS, Paz N, Hall CP, Song MM, Calderon RI, Cruz RE, Hindle A, Ko W, Fitzgerald JB, Drummond DC, Triche TJ, Reynolds CP. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1139-50. PMID 25733708 DOI: 10.1158/1078-0432.Ccr-14-1882 |
0.451 |
|
| 2015 |
Butowski NA, Han S, Taylor JW, Aghi MK, Prados M, Chang SM, Clarke JL, Bankiewicz K, Drummond DC, Fitzgerald J. A phase I study of convection-enhanced delivery of nanoliposomal irinotecan using real-time imaging in patients with recurrent high grade glioma. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps2081 |
0.485 |
|
| 2015 |
Raue A, Alkan O, Drummond D, Schoeberl B. Abstract B2-34: Model guided understanding of synergistic combination therapies in the DNA damage response pathway Cancer Research. 75. DOI: 10.1158/1538-7445.Compsysbio-B2-34 |
0.329 |
|
| 2014 |
Kalra AV, Kim J, Klinz SG, Paz N, Cain J, Drummond DC, Nielsen UB, Fitzgerald JB. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Research. 74: 7003-13. PMID 25273092 DOI: 10.1158/0008-5472.Can-14-0572 |
0.479 |
|
| 2014 |
Noble CO, Krauze MT, Drummond DC, Forsayeth J, Hayes ME, Beyer J, Hadaczek P, Berger MS, Kirpotin DB, Bankiewicz KS, Park JW. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors. Nanomedicine (London, England). 9: 2099-108. PMID 24494810 DOI: 10.2217/Nnm.13.201 |
0.713 |
|
| 2014 |
Chan DC, Kalra A, Zhang Z, Paz N, Kirpotin D, Drummond D, Nielsen U, Bunn PA, Fitzgerald J. Abstract 4626: Evaluating the pharmacodynamics and pharmacokinetic effects of MM-398, a nanoliposomal irinotecan (nal-IRI) in subcutaneous xenograft tumor models of human squamous cell carcinoma and small cell lung cancers Cancer Research. 74: 4626-4626. DOI: 10.1158/1538-7445.Am2014-4626 |
0.459 |
|
| 2014 |
Kang MH, Song MM, Makena M, Lee J, Hall CP, Hindle A, Ko W, Paz N, Fitzgerald J, Drummond DC, Triche TJ, Reynolds CP. Abstract 3972: Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewings family tumor xenografts is associated with high exposure of tumor to drug and highSLFN11expression Cancer Research. 74: 3972-3972. DOI: 10.1158/1538-7445.Am2014-3972 |
0.46 |
|
| 2014 |
Kalra AV, Spernyak J, Kim J, Sengooba A, Klinz S, Paz N, Cain J, Kamoun W, Straubinger N, Qu Y, Trueman S, Bayever E, Nielsen U, Drummond D, Fitzgerald J, et al. Abstract 2065: Magnetic resonance imaging with an iron oxide nanoparticle demonstrates the preclinical feasibility of predicting intratumoral uptake and activity of MM-398, a nanoliposomal irinotecan (nal-IRI) Cancer Research. 74: 2065-2065. DOI: 10.1158/1538-7445.Am2014-2065 |
0.668 |
|
| 2013 |
Weng KC, Hashizume R, Noble CO, Serwer LP, Drummond DC, Kirpotin DB, Kuwabara AM, Chao LX, Chen FF, James CD, Park JW. Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models. Nanomedicine (London, England). 8: 1913-25. PMID 23631502 DOI: 10.2217/Nnm.12.209 |
0.709 |
|
| 2013 |
Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, Wei KC, Butowski N, Prados MD, Berger MS, Forsayeth JR, Bankiewicz K, James CD. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro-Oncology. 15: 189-97. PMID 23262509 DOI: 10.1093/Neuonc/Nos305 |
0.432 |
|
| 2013 |
Kalra A, Kim J, Klinz S, Paz N, Reutt J, Drummond D, Kirpotin D, Moyo V, Bayever E, Laivins P, Niyikiza C, Nielsen U, Fitzgerald J. Abstract 5622: The tumor microenvironment modulates the delivery and activation of liposomal encapsulated irinotecan, MM-398. Cancer Research. 73: 5622-5622. DOI: 10.1158/1538-7445.Am2013-5622 |
0.481 |
|
| 2012 |
Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Klinz SG, Noble CO, Lücker PB, Zandstra PW, Drummond DC, Olivier KJ, Nielsen UB, Niyikiza C, Agresta SV, Wickham TJ. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicology and Applied Pharmacology. 262: 1-10. PMID 22676972 DOI: 10.1016/J.Taap.2012.04.008 |
0.708 |
|
| 2012 |
Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks JD, Drummond DC. Building and characterizing antibody-targeted lipidic nanotherapeutics. Methods in Enzymology. 502: 139-66. PMID 22208985 DOI: 10.1016/B978-0-12-416039-2.00007-0 |
0.723 |
|
| 2012 |
Paz N, Laivins P, Niyikiza C, Nielsen U, Fitzgerald J, Kalra A, Chalishazar M, Klinz S, Kim J, Drummond D, Kirpotin D, Moyo V, Bayever E. Abstract A63: MM-398/PEP02, a novel liposomal formulation of irinotecan, demonstrates stromal-modifying anticancer properties. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-A63 |
0.455 |
|
| 2012 |
Kim J, Bayever E, Laivins P, Niyikiza C, Nielsen U, Fitzgerald J, Kalra A, Chalishazar M, Klinz S, Paz N, Hendriks B, Drummond D, Kirpotin D, Moyo V. Abstract A6: Sustained intratumoral activation of MM-398 results in superior activity over irinotecan demonstrated by using a systems pharmacology approach Cancer Research. 72. DOI: 10.1158/1538-7445.Csb12-A6 |
0.466 |
|
| 2012 |
Kalra A, Klinz S, Paz N, Kim J, Chalishazar M, Drummond D, Kirpotin D, Moyo V, Niyikiza C, Fitzgerald J. Abstract 5696: Evaluating determinants for enhanced activity of MM-398/PEP02; a novel nanotherapeutic encapsulation of irinotecan (CPT-11) Cancer Research. 72: 5696-5696. DOI: 10.1158/1538-7445.Am2012-5696 |
0.485 |
|
| 2012 |
Lee H, Zheng J, Gaddy D, Kirpotin D, Dunne M, Drummond D, Allen C, Jaffray D, Hendriks B, Wickham T. Abstract P4-02-05: A novel 64Cu-liposomal PET agent (MM-DX-929) predicts response to liposomal chemotherapeutics in preclinical breast cancer models Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P4-02-05 |
0.449 |
|
| 2012 |
Yang FH, Zhang B, Zhou DJ, Bie L, Tom MW, Drummond DC, Nicolaides T, Mueller S, Banerjee A, Park JW, Prados MD, James DC, Gupta N, Hashizume R, Strohbehn GW, ... ... Drummond D, et al. LAB-EXPERIMENTAL (PRE-CLINICAL) THERAPEUTICS AND PHARMACOLOGY Neuro-Oncology. 14: vi25-vi37. DOI: 10.1093/Neuonc/Nos222 |
0.303 |
|
| 2011 |
Serwer LP, Noble CO, Michaud K, Drummond DC, Kirpotin DB, Ozawa T, Prados MD, Park JW, James CD. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Neuro-Oncology. 13: 1288-95. PMID 21954443 DOI: 10.1093/Neuonc/Nor139 |
0.751 |
|
| 2011 |
Wang J, Zhuo R, Drummond D, Reynolds CP, Kang MH. Abstract 5469: Pharmacokinetics and activity of nanoliposomal irinotecan (MM-398) against Ewings Sarcoma xenografts are superior to the conventional irinotecan formulation Cancer Research. 71: 5469-5469. DOI: 10.1158/1538-7445.Am2011-5469 |
0.45 |
|
| 2011 |
Klinz SG, Paz N, Kalra A, Kim J, Hendriks B, Drummond D, Kirpotin D, Moyo V, Yeh CG, Niyikiza C, Fitzgerald J. Abstract C207: Identifying differential mechanisms of action for MM-398/PEP02, a novel nanotherapeutic encapsulation of irinotecan. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C207 |
0.48 |
|
| 2011 |
Pavel H, Ajeawung N, Faure R, Poirier D, Kamnasaran D, Ajeawung N, Joshi H, Kamnasaran D, Poirier D, Ajeawung N, Kamnasaran D, Lun X, Zemp F, Sun B, Stechishin O, ... ... Drummond DC, et al. PRECLINICAL EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY Neuro-Oncology. 13: iii107-iii120. DOI: 10.1093/Neuonc/Nor158 |
0.67 |
|
| 2010 |
Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Larson RF, Yamashita Y, Krauze MT, Forsayeth J, Noble CO, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS. Canine spontaneous glioma: a translational model system for convection-enhanced delivery. Neuro-Oncology. 12: 928-40. PMID 20488958 DOI: 10.1093/Neuonc/Noq046 |
0.731 |
|
| 2010 |
Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB. Development of a highly stable and targetable nanoliposomal formulation of topotecan. Journal of Controlled Release : Official Journal of the Controlled Release Society. 141: 13-21. PMID 19686789 DOI: 10.1016/J.Jconrel.2009.08.006 |
0.738 |
|
| 2010 |
Wickham T, Reynolds J, Drummond D, Kirpotin D, Lahdenranta J, Leonard S, Geretti E, Lee H, Klinz S, Hendriks B, Olivier K, Eckelhofer I, Park J, Benz C, Moyo V, et al. Abstract P3-14-09: Preclinical Safety and Activity of MM-302, a HER2-Targeted Liposomal Doxorubicin Designed To Have an Improved Safety and Efficacy Profile over Approved Anthracyclines Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-14-09 |
0.503 |
|
| 2009 |
Noble CO, Guo Z, Hayes ME, Marks JD, Park JW, Benz CC, Kirpotin DB, Drummond DC. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemotherapy and Pharmacology. 64: 741-51. PMID 19184019 DOI: 10.1007/S00280-008-0923-3 |
0.722 |
|
| 2009 |
Drummond DC, Noble CO, Guo Z, Hayes ME, Park JW, Ou CJ, Tseng YL, Hong K, Kirpotin DB. Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. The Journal of Pharmacology and Experimental Therapeutics. 328: 321-30. PMID 18948499 DOI: 10.1124/Jpet.108.141200 |
0.745 |
|
| 2008 |
Weng KC, Noble CO, Papahadjopoulos-Sternberg B, Chen FF, Drummond DC, Kirpotin DB, Wang D, Hom YK, Hann B, Park JW. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Letters. 8: 2851-7. PMID 18712930 DOI: 10.1021/Nl801488U |
0.691 |
|
| 2008 |
Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Roberts B, Larson RF, Yamashita Y, Krauze M, Noble CO, Drummond D, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS. Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. Journal of Neurosurgery. 108: 989-98. PMID 18447717 DOI: 10.3171/Jns/2008/108/5/0989 |
0.712 |
|
| 2008 |
Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. Journal of Pharmaceutical Sciences. 97: 4696-740. PMID 18351638 DOI: 10.1002/Jps.21358 |
0.712 |
|
| 2008 |
An F, Drummond DC, Wilson S, Kirpotin DB, Nishimura SL, Broaddus VC, Liu B. Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Molecular Cancer Therapeutics. 7: 569-78. PMID 18319332 DOI: 10.1158/1535-7163.MCT-07-2132 |
0.337 |
|
| 2007 |
Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, Marks JD, Liu B. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Molecular Cancer Therapeutics. 6: 2737-46. PMID 17938267 DOI: 10.1158/1535-7163.Mct-07-0140 |
0.446 |
|
| 2007 |
Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y, Kullberg E, Forsayeth J, Park JW, Bankiewicz KS. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro-Oncology. 9: 393-403. PMID 17652269 DOI: 10.1215/15228517-2007-019 |
0.765 |
|
| 2007 |
Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. Journal of Molecular Biology. 371: 934-47. PMID 17602702 DOI: 10.1016/J.Jmb.2007.05.011 |
0.383 |
|
| 2007 |
Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD. Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. Journal of Molecular Medicine (Berlin, Germany). 85: 1113-23. PMID 17554518 DOI: 10.1007/S00109-007-0208-Z |
0.388 |
|
| 2007 |
Goenaga AL, Zhou Y, Legay C, Bougherara H, Huang L, Liu B, Drummond DC, Kirpotin DB, Auclair C, Marks JD, Poul MA. Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies Molecular Immunology. 44: 3777-3788. PMID 17498801 DOI: 10.1016/J.Molimm.2007.03.023 |
0.378 |
|
| 2007 |
Yamashita Y, Krauze MT, Kawaguchi T, Noble CO, Drummond DC, Park JW, Bankiewicz KS. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro-Oncology. 9: 20-8. PMID 17018695 DOI: 10.1215/15228517-2006-016 |
0.743 |
|
| 2006 |
Hayes ME, Drummond DC, Hong K, Zheng WW, Khorosheva VA, Cohen JA, Noble IV CO, Park JW, Marks JD, Benz CC, Kirpotin DB. Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation Molecular Pharmaceutics. 3: 726-736. PMID 17140260 DOI: 10.1021/Mp060040V |
0.322 |
|
| 2006 |
Nielsen UB, Kirpotin DB, Pickering EM, Drummond DC, Marks JD. A novel assay for monitoring internalization of nanocarrier coupled antibodies. Bmc Immunology. 7: 24. PMID 17014727 DOI: 10.1186/1471-2172-7-24 |
0.416 |
|
| 2006 |
Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Research. 66: 6732-40. PMID 16818648 DOI: 10.1158/0008-5472.Can-05-4199 |
0.514 |
|
| 2006 |
Saito R, Krauze MT, Noble CO, Drummond DC, Kirpotin DB, Berger MS, Park JW, Bankiewicz KS. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro-Oncology. 8: 205-14. PMID 16723630 DOI: 10.1215/15228517-2006-001 |
0.738 |
|
| 2006 |
Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Research. 66: 3271-7. PMID 16540680 DOI: 10.1158/0008-5472.Can-05-4007 |
0.738 |
|
| 2006 |
Noble CO, Krauze MT, Drummond DC, Yamashita Y, Saito R, Berger MS, Kirpotin DB, Bankiewicz KS, Park JW. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Research. 66: 2801-6. PMID 16510602 DOI: 10.1158/0008-5472.Can-05-3535 |
0.715 |
|
| 2006 |
Saito R, Krauze MT, Noble CO, Tamas M, Drummond DC, Kirpotin DB, Berger MS, Park JW, Bankiewicz KS. Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. Journal of Neuroscience Methods. 154: 225-32. PMID 16472868 DOI: 10.1016/J.Jneumeth.2005.12.027 |
0.701 |
|
| 2006 |
Hayes ME, Drummond DC, Kirpotin DB, Zheng WW, Noble CO, Park JW, Marks JD, Benz CC, Hong K. Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Therapy. 13: 646-51. PMID 16341056 DOI: 10.1038/Sj.Gt.3302699 |
0.674 |
|
| 2006 |
Goldkorn A, Hann B, Hayes M, Drummond DC, Kirpotin DB, Peth K, Marks JD, Blackburn EH, Park JW. Systemic telomerase gene therapy delivered via targeted lipidic nanoparticles Journal of Clinical Oncology. 24: 13025-13025. DOI: 10.1200/Jco.2006.24.18_Suppl.13025 |
0.414 |
|
| 2006 |
Yamashita Y, Saito R, Krauze MT, Kawaguchi T, Noble C, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS. Convection-enhanced delivery of liposomal doxorubicin in intracranial brain tumor xenografts Targeted Oncology. 1: 79-85. DOI: 10.1007/S11523-006-0011-8 |
0.739 |
|
| 2005 |
Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Research. 65: 11631-8. PMID 16357174 DOI: 10.1158/0008-5472.Can-05-1093 |
0.751 |
|
| 2005 |
Saito R, Krauze MT, Bringas JR, Noble C, McKnight TR, Jackson P, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Hong K, Berger MS, Park JW, Bankiewicz KS. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Experimental Neurology. 196: 381-9. PMID 16197944 DOI: 10.1016/J.Expneurol.2005.08.016 |
0.732 |
|
| 2005 |
Nellis DF, Giardina SL, Janini GM, Shenoy SR, Marks JD, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, Perkins SC, Kirpotin DB. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnology Progress. 21: 221-32. PMID 15903261 DOI: 10.1021/Bp049839Z |
0.34 |
|
| 2005 |
Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, Hong K, Marks JD, Park JW, Giardina SL. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnology Progress. 21: 205-20. PMID 15903260 DOI: 10.1021/Bp049840Y |
0.351 |
|
| 2005 |
Drummond DC, Marx C, Guo Z, Scott G, Noble C, Wang D, Pallavicini M, Kirpotin DB, Benz CC. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3392-401. PMID 15867240 DOI: 10.1158/1078-0432.Ccr-04-2445 |
0.72 |
|
| 2005 |
Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annual Review of Pharmacology and Toxicology. 45: 495-528. PMID 15822187 DOI: 10.1146/Annurev.Pharmtox.45.120403.095825 |
0.678 |
|
| 2004 |
Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. Development of ligand-targeted liposomes for cancer therapy. Expert Opinion On Therapeutic Targets. 8: 335-53. PMID 15268628 DOI: 10.1517/14728222.8.4.335 |
0.692 |
|
| 2004 |
Mamot C, Nguyen JB, Pourdehnad M, Hadaczek P, Saito R, Bringas JR, Drummond DC, Hong K, Kirpotin DB, McKnight T, Berger MS, Park JW, Bankiewicz KS. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. Journal of Neuro-Oncology. 68: 1-9. PMID 15174514 DOI: 10.1023/B:Neon.0000024743.56415.4B |
0.462 |
|
| 2004 |
Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Research. 64: 2572-9. PMID 15059914 DOI: 10.1158/0008-5472.Can-03-3631 |
0.474 |
|
| 2004 |
Mamot C, Rochlitz C, Herrmann R, Küng W, Ritschard R, Reuter J, Drummond DC, Hong K, Kirpotin DB, Park JW. 298 Development of anti-EGFR immunoliposomes for specific delivery and enhanced efficacy in EGFR-overexpressing tumors Ejc Supplements. 2: 91. DOI: 10.1016/S1359-6349(04)80306-9 |
0.4 |
|
| 2003 |
Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. Liposome-based approaches to overcome anticancer drug resistance. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 6: 271-9. PMID 14643297 DOI: 10.1016/S1368-7646(03)00082-7 |
0.517 |
|
| 2003 |
Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells Cancer Research. 63: 3154-3161. PMID 12810643 DOI: 10.1080/14733400410001727592 |
0.377 |
|
| 2002 |
Banerjee M, Drummond DC, Srivastava A, Daleke D, Lentz BR. Specificity of soluble phospholipid binding sites on human factor Xa. Biochemistry. 41: 7751-62. PMID 12056907 DOI: 10.1021/Bi020017P |
0.635 |
|
| 2002 |
Zhai X, Srivastava A, Drummond DC, Daleke D, Lentz BR. Phosphatidylserine binding alters the conformation and specifically enhances the cofactor activity of bovine factor Va. Biochemistry. 41: 5675-84. PMID 11969429 DOI: 10.1021/Bi011844D |
0.635 |
|
| 2001 |
Leroux J, Roux E, Le Garrec D, Hong K, Drummond DC. N-isopropylacrylamide copolymers for the preparation of pH-sensitive liposomes and polymeric micelles. Journal of Controlled Release : Official Journal of the Controlled Release Society. 72: 71-84. PMID 11389986 DOI: 10.1016/S0168-3659(01)00263-2 |
0.315 |
|
| 2000 |
Drummond DC, Zignani M, Leroux J. Current status of pH-sensitive liposomes in drug delivery. Progress in Lipid Research. 39: 409-460. PMID 11082506 DOI: 10.1016/S0163-7827(00)00011-4 |
0.361 |
|
| 2000 |
Drummond DC, Hong K, Park JW, Benz CC, Kirpotin DB. Liposome targeting to tumors using vitamin and growth factor receptors. Vitamins and Hormones Series. 60: 285-332. PMID 11037627 DOI: 10.1016/S0083-6729(00)60022-5 |
0.411 |
|
| 2000 |
Zignani M, Drummond DC, Meyer O, Hong K, Leroux J. In vitro characterization of a novel polymeric-based pH-sensitive liposome system. Biochimica Et Biophysica Acta. 1463: 383-394. PMID 10675515 DOI: 10.1016/S0005-2736(99)00234-5 |
0.311 |
|
| Show low-probability matches. |